Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Tracking Information | |
|---|---|
| First Received Date ICMJE | April 14, 2008 |
| Last Updated Date | May 27, 2011 |
| Start Date ICMJE | March 2008 |
| Primary Completion Date | May 2008 (final data collection date for primary outcome measure) |
| Current Primary Outcome Measures ICMJE |
|
| Original Primary Outcome Measures ICMJE |
For every study treatment/dialyzer, the nursing staff will complete a questionnaire regarding the ease of priming and rinse-back, and visually assess residual blood and clots in the dialyzer after rinse-back. [ Time Frame: Priming and rinse-back of each dialyzer ] [ Designated as safety issue: No ] |
| Change History | Complete list of historical versions of study NCT00659724 on ClinicalTrials.gov Archive Site |
| Current Secondary Outcome Measures ICMJE | Not Provided |
| Original Secondary Outcome Measures ICMJE | Not Provided |
| Current Other Outcome Measures ICMJE | Not Provided |
| Original Other Outcome Measures ICMJE | Not Provided |
| Descriptive Information | |
| Brief Title ICMJE | Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer |
| Official Title ICMJE | The Gambro Polyflux HD-C4 Big Ease Of Use And Thrombogenicity Study |
| Brief Summary | The purpose of this study is to collect information on the ease of use and thrombogenicity of the Polyflux HD-C4 Big and Fresenius Optiflux 180NR or 200NR dialyzers under conditions of routine clinical use for hemodialysis. |
| Detailed Description | This ease of use study involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy. This study is aimed at obtaining feedback from the nursing and technical staff regarding the use and thrombogenicity of the Polyflux HD-C4 Big, and Fresenius Optiflux 180NR or 200NR dialyzers. The dialysis nursing staff will complete ease of use and thrombogenicity assessments following routine dialysis therapy. Any adverse events will be tracked for the study patients. |
| Study Type ICMJE | Observational |
| Study Design ICMJE | Time Perspective: Prospective |
| Target Follow-Up Duration | Not Provided |
| Biospecimen | Not Provided |
| Sampling Method | Non-Probability Sample |
| Study Population | Assessment of dialyzer ease of use and thrombogenicity assessments following routine dialysis therapy of 33 adult patients (18 years of age or older) |
| Condition ICMJE | Chronic Kidney Failure |
| Intervention ICMJE | Not Provided |
| Study Group/Cohort (s) | Not Provided |
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Recruitment Status ICMJE | Completed |
| Enrollment ICMJE | 33 |
| Completion Date | May 2008 |
| Primary Completion Date | May 2008 (final data collection date for primary outcome measure) |
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
| Gender | Both |
| Ages | 18 Years and older |
| Accepts Healthy Volunteers | No |
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
| Location Countries ICMJE | United States |
| Administrative Information | |
| NCT Number ICMJE | NCT00659724 |
| Other Study ID Numbers ICMJE | Gambro 1462 |
| Has Data Monitoring Committee | No |
| Responsible Party | Jeffrey Shideman, Ph.D., Director US Clinical Affairs, Gambro Renal Products, Inc. |
| Study Sponsor ICMJE | Gambro Renal Products, Inc. |
| Collaborators ICMJE |
|
| Investigators ICMJE | Not Provided |
| Information Provided By | Gambro Renal Products, Inc. |
| Verification Date | May 2011 |
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|